Author

Levine L

Barbara and Edward Netter Professor in Cancer Gene Therapy, Department of Pathology and Laboratory - Cited by 63,916

Biography

Levine L is working in the Department of Obstetrics and Gynecology of UTMB-Health located in USA. He has got international experience includes various programs, contributions and participation in different countries for diverse fields of study.
Title
Cited by
Year
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
JJ Melenhorst, GM Chen, M Wang, DL Porter, C Chen, MKA Collins, ...Nature 602 (7897), 503-509, 2022202
263
2022
Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia
RM Myers, Y Li, AB Leahy, DM Barrett, DT Teachey, C Callahan, ...Journal of Clinical Oncology 39 (27), 3044, 2021202
76
2021
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
P Tebas, JK Jadlowsky, PA Shaw, L Tian, E Esparza, AL Brennan, S Kim, ...The Journal of clinical investigation 131 (7), 2021202
40
2021
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia
W Kong, A Dimitri, W Wang, IY Jung, CJ Ott, M Fasolino, Y Wang, ...The Journal of Clinical Investigation 131 (16), 1-16, 2021202
37
2021
Advances in automated cell washing and concentration
A Li, GD Kusuma, D Driscoll, N Smith, DM Wall, BL Levine, D James, ...Cytotherapy 23 (9), 774-786, 2021202
18
2021
The coronavirus pandemic: a pitfall or a fast track for validating cell therapy products?
M Khoury, L Ikonomou, M Dominici, K LeBlanc, BL Levine, DJ WeissStem Cells and Development 30 (3), 119-127, 2021202
10
2021
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T1C Diorio, R Shraim, R Myers, EM Behrens, S Canna, H Bassiri, R Aplenc, ...Clinical Cancer Research 28 (17), 3804-3813, 2022202
9
2022
The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma
SH Manjunath, AD Cohen, SF Lacey, MM Davis, AL Garfall, JJ Melenhorst, ...Clinical Cancer Research 27 (23), 6580-650, 2021202
9
2021
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici, M Gohil, S Lundh, ...Nature Medicine 27 (3), 561-562, 2021202
8
2021
Production of human Crispr-engineered Car-T cells
S Agarwal, N Wellhausen, BL Levine, CH JuneJoVE (Journal of Visualized Experiments), e62299, 2021202
8
2021
Adoptive T-cell therapy for Hodgkin lymphoma
C Ho, M Ruella, BL Levine, J SvobodaBlood Advances 5 (20), 4291-4302, 2021202
8
2021
Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products
N Cuende, R Ciccocioppo, M Forte, J Galipeau, L Ikonomou, BL Levine, ...Cytotherapy 24 (7), 66-690, 2022202
8
2022
CART22-65s co-administered with huCART19 in adult patients with relapsed or refractory all
CART22-5s co-administered with huCART19 in adult patients with relapsed or refractory allNV Frey, S Gill, WT Hwang, SM Luger, ME Martin, SR McCurdy, AW Loren, ...Blood 138, 49, 2021202
6
2021
Methods for improving the efficacy and expansion of immune cells
F Bedoya, S Ghassemi, CH June, OU Kawalekar, BL Levine, ...US Patent App. 17/025,732, 2021202
6
2021
Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells
JJ Melenhorst, GM Chen, M Wang, DL Porter, P Gao, S Bandyopadhyay, ...Blood 138, 166, 2021202
5
2021
Engineering T cells to survive and thrive in the hostile tumor microenvironment
GB Kim, JL Riley, BL LevineCurrent Opinion in Biomedical Engineering 21, 100360, 2022202
5
2022
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma
MH Qazilbash, NY Saini, S Cha, Z Wang, EA Stadtmauer, ...Blood, The Journal of the American Society of Hematology 139 (9), 1289-1301, 2022202
5
2022
Predicting T‐cell quality during manufacturing through an artificial intelligence‐based integrative multiomics analytical platform
VY Odeh‐Couvertier, NJ Dwarshuis, MB Colonna, BL Levine, AS Edison, ...Bioengineering & Translational Medicine 7 (2), e10282, 2022202
5
2022
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination …
L Bernabei, L Tian, AL Garfall, JJ Melenhorst, SF Lacey, EA Stadtmauer, ...British journal of haematology 193 (4), 851-855, 010
2
2021
Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors
IY Jung, E Noguera-Ortega, R Bartoszek, SM Collins, E Williams, M Davis, ...Cell Reports Medicine 4 (6), 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=F58KM9YAAAAJ&hl=en

Cited by
Citations 63916
h-index 107
i10-index 249
Open Access Journals